PDGFR-beta Inhibitors
Santa Cruz Biotechnology now offers a broad range of PDGFR-beta Inhibitors. The biological effects of Platelet-derived growth factor (PDGF) proteins are mediated via two tyrosine kinase receptors, PDGFR-α and PDGFR-β. PDGF-mediated signaling is critical for development of many organ systems and is important for growth and survival. PDGFR-beta Inhibitors offered by Santa Cruz inhibit PDGFR-beta and, in some cases, other development and tyrosine kinase receptor related proteins. View detailed PDGFR-beta Inhibitor specifications, including PDGFR-beta Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 11 to 20 of 44 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SU 6668 | 252916-29-3 | sc-204309 sc-204309A | 10 mg 50 mg | $127.00 $712.00 | 2 | |
SU 6668, functions as a potent inhibitor of PDGFR-beta, a key player in cellular signaling. By targeting PDGFR-beta, it modulates specific pathways, holding relevance in diverse biological contexts. | ||||||
PDGFR Tyrosine Kinase Inhibitor IV | 627518-40-5 | sc-205794 sc-205794A sc-205794B sc-205794C | 1 mg 5 mg 10 mg 50 mg | $28.00 $141.00 $262.00 $1150.00 | 2 | |
PDGFR Tyrosine Kinase Inhibitor IV, effectively targets and inhibits PDGFR-beta, a crucial protein involved in cellular signaling pathways. It offers potential insights into modulating specific cellular processes. | ||||||
Tie2 Kinase Inhibitor Inhibitor | 948557-43-5 | sc-356156 | 5 mg | $360.00 | ||
Tie2 Kinase Inhibitor, effectively hampers PDGFR-beta, a significant protein in cellular signaling. By targeting this interaction, it modulates specific pathways, holding relevance in diverse biological investigations. | ||||||
Crenolanib | 670220-88-9 | sc-364470 sc-364470A | 5 mg 10 mg | $612.00 $1020.00 | ||
Crenolanib is a tyrosine kinase inhibitor that specifically targets PDGFR-β and FLT3, and it's being investigated for various cancers, including acute myeloid leukemia. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib is a triple angiokinase inhibitor that targets PDGFR-β, VEGFR, and FGFR. It's studied in the research of idiopathic pulmonary fibrosis and certain types of advanced non-small cell lung cancer. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib targets various kinases, including PDGFR-Beta. | ||||||
DMPQ dihydrochloride | 137206-97-4 | sc-203927 sc-203927A | 10 mg 50 mg | $150.00 $605.00 | 1 | |
DMPQ dihydrochloride (CAS 137206-97-4) functions as an inhibitor of PDGFR-beta, a crucial protein in cellular signaling. By targeting this interaction, it modulates specific pathways, holding relevance for diverse biological investigations. | ||||||
PDGFR/VEGFR2 Tyrosine Kinase Inhibitor, 5-Br SU6668 | sc-222143 | 5 mg | $333.00 | |||
The compound known as PDGFR/VEGFR2 Tyrosine Kinase Inhibitor, 5-Br SU6668, effectively inhibits PDGFR-beta. It modulates specific cellular pathways by targeting this interaction, with potential significance in various biological studies. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib inhibits PDGFR-Beta and other kinases. | ||||||
AG 1433 Hydrochloride | sc-221220 | 5 mg | $117.00 | |||
AG 1433 Hydrochloride acts as an inhibitor of PDGFR-beta, a vital protein in cellular signaling. By targeting this interaction, it influences specific pathways, offering potential insights into diverse biological processes. | ||||||